Paul Peter Tak

Paul Peter Tak

Company: Candel Therapeutics

Job title: Chief Executive Officer & President


Viral Immunotherapy for Solid Tumors: The New Frontier 2:00 pm

CAN-2409 treatment is a systemic immunotherapy delivered intra-tumorally, which induces a CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases. It is being tested in the clinic across multiple solid tumors CAN-3110 is a replication-competent HSV gene construct, which is able to replicate specifically in tumor cells while sparing healthy tissue. It…Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.